Autopsy report · NCT03879811

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

“No accrual”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

Sponsor type

University, hospital or other

Conditions

Colorectal Cancer

Interventions

TMZ; Nivolumab

Participants

0

Trials that died the same way

• A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
  “No accruals” (96% match in meaning)
• Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
  “0 accrual” (83% match in meaning)
• Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer
  “non-accrual” (82% match in meaning)
• Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
  “poor accrual” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.